<DOC>
	<DOCNO>NCT00563446</DOCNO>
	<brief_summary>Anaemia common consequence chronic renal failure . Darbepoetin alfa unique erythropoietic protein stimulate erythropoiesis mechanism endogenous erythropietin conventional recombinant human erythropoietin ( rHuEPO ) . Darbepoetin alfa show serum half-life 3-fold long rHuEPO , allow dose extend interval less frequent injection . The objective evaluate efficacy safety darbepoetin alfa therapy give extend monthly dose interval treatment renal anaemia continuous ambulatory peritoneal dialysis .</brief_summary>
	<brief_title>Study Efficacy Darbepoetin Alfa Treatment Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Patients continuous ambulatory peritoneal dialysis Patients receive subcutaneous recombinant human erythropoietin ( rHuEPO ) Patients haemoglobin level ? 10 g/dL remain stable past 3 month receive rHuEPO Uncontrolled hypertension Severe congestive heart failure ( NYHA class III IV ) Grand mal epilepsy Any kind blood loss cause Fe depletion Presence infection , either acute chronic , inflammatory condition within 3 month precede study Malignancy Aluminum toxicity Severe hyperparathyroidism marrow fibrosis osteitis fibrosa _ PTH &gt; 20 time normal Vitamin B12 folate deficiency _ MCV &gt; 100fL Haemolysis Marrow dysfunction e.g . aplastic anaemia , myelodysplastic syndrome , multiple myeloma , etc Thalassaemia major , intermediate minor , red cell enzyme defect Blood transfusion within 3 month precede study Pregnancy lactate mother</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Anemia</keyword>
	<keyword>End-stage renal failure</keyword>
	<keyword>Continuous ambulatory peritoneal dialysis</keyword>
</DOC>